Home
|
Contact us
|
Disclaimer
Corporate Overview
Management
Board of Directors
Business Ethics
Contact us
Product pipeline
ELND005
Anti-inflammation
Anti-diabetes compounds
Current partnership
In/Out-licensing opportunity
ELND005 Phase II
Stock quote
Financial reports
Analyst coverage
Request information
Subscribe to e-mail alert
Press release 2011
Press release archive
Webcast and presentation
INVESTOR relations
Stock Quotes
Financial Reports
Analyst Coverage
Request Information
E-mail Alert
You may automatically receive Transition Therapeutics' press releases by e-mail. Please fill out the form below to subscribe or unsubscribe the e-mail alert:
Action:
Subscribe
Unsubscribe
E-mail Address:
© 2011 Transition Therapeutics Inc.